SAMUEL POTTER: Open Payments
NPI 1407563109 · MAGNA, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,129 in 82 payments from 26 companies in 2025. Trend: 2023 $304 · 2024 $1,266 · 2025 $2,129
Food & beverage: $2,129
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $387 |
| Edwards Lifesciences Corporation | 1 | $202 |
| AstraZeneca Pharmaceuticals LP | 5 | $194 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $192 |
| Indivior Inc. | 8 | $186 |
| Novo Nordisk Inc | 4 | $161 |
| GlaxoSmithKline, LLC. | 3 | $131 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Corcept Therapeutics | 3 | $64 |
| Boston Scientific Corporation | 2 | $53 |
Products named: VRAYLAR, SAPIEN 3 Ultra RESILIA, CAPLYTA, SUBLOCADE, Ozempic, VOQUEZNA, AREXVY, QULIPTA.
Industry payments across UT — which companies pay providers there.
